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The high mortality of COVID-19 is mostly attributed to acute respiratory distress
syndrome (ARDS), whose histopathological correlate is diffuse alveolar damage (DAD).
Furthermore, severe COVID-19 is often accompanied by a cytokine storm and
a disrupted response of the adaptive immune system. Studies aiming to depict
this dysregulation have mostly investigated the peripheral cell count as well as
the functionality of immune cells. We investigated the impact of SARS-CoV-2 on
antigen-presenting cells using multiplexed immunofluorescence. Similar to MERS-CoV
and SARS-CoV, SARS-CoV-2 appears to be impairing the maturation of dendritic cells
(DCs). DC maturation involves a switch in surface antigen expression, which enables the
cells’ homing to lymph nodes and the subsequent activation of T-cells. As quantitative
descriptions of the local inflammatory infiltrate are still scarce, we compared the cell
population of professional antigen-presenting cells (APC) in the lungs of COVID-19
autopsy cases in different stages of DAD. We found an increased count of myeloid
dendritic cells (mDCs) in later stages. Interestingly, mDCs also showed no significant
upregulation of maturation markers in DAD-specimens with high viral load. Accumulation
of immature mDCs, which are unable to home to lymph nodes, ultimately results in an
inadequate T-cell response.
Keywords: dendritic cells, maturation, homing, SARS-CoV-2, COVID-19, diffuse alveolar damage (DAD),
multiplexed immunofluorescence, artificial intelligence
INTRODUCTION
Respiratory failure/acute respiratory distress syndrome (ARDS) has been identified as the leading
cause of death in COVID-19 by numerous studies (1–4). Diffuse alveolar damage (DAD) is the
usual histopathological correlate of COVID-associated ARDS (5–10). Complications contributing
to organ failure and death in severe cases of COVID-19 include a dysregulated immune system
accompanied by a cytokine storm (11, 12). Previous attempts to substantiate this dysregulation
mostly investigated the peripheral blood cell count or performed single-cell analyses, while some
have used immunohistochemistry or immunofluorescence to depict the inflammatory infiltrate
(9, 13–15).
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The role of dendritic cells (DCs) in COVID-19 has only
recently begun to attract the attention of researchers. DC
numbers in bronchoalveolar lavage fluids (BALF) decrease
in later stages of COVID-19 (16). The term “dendritic cell”
is used to describe functionally similar cells of different
origins, both capable of activating T cells and inducing an
adaptive immune response. CD11c− plasmacytoid dendritic cells
(pDCs) derive from a lymphoid precursor, whereas CD11c+
myeloid/conventional dendritic cells (mDCs/cDCs) are closely
related to monocytes and derive from a myeloid progenitor
cell. (17) Dendritic cells can be thought of as a link between
the innate and the adaptive immune system (18). While they
usually only make up for a small part of immune cells in lungs
(19), their number rapidly increases shortly after the onset of an
inflammatory process. In most cases, a normalization of the DC
count can be observed after resolving the inflammation, although
there are some reports of a hampered restitution of the count in
some viral inflammations (17). In COVID-19, there seems to be
a decline in the count of pDCs (20) and a shift toward mDCs
(21, 22) in the peripheral blood.
To our knowledge no attempt has been made yet to correlate
the inflammatory infiltrate with various stages of diffuse alveolar
damage. Here, we quantified professional antigen-presenting




Lung tissue was acquired from all COVID-19 associated autopsy
cases of the University Medical Center of Augsburg, Germany,
during the local first wave of the pandemic in 2020 (n = 19,
Table 1). All patients had been tested positive for SARS-CoV-2.
Post-mortem SARS-CoV-2 RNA was detectable in swabs of the
upper and lower airways (Pharynx, Trachea, and Bronchus) at
the time of autopsy in all but two cases via RT-qPCR (S-gene, N-
gene, ORF1-gene). Respiratory insufficiency was the determining
cause of death in 12 cases, while all but one of the remaining
causes (septic shock) were COVID-associated, too. One patient
had died of cardiac failure, showing only limited DAD patterns
in the lungs.
Respecting the wish of their next of kin, a minimal or full-
body autopsy was performed, resulting in a variable number of
investigated lung lobes per patient. Out of each available lung
lobe, three samples were taken, formalin-fixated and paraffin-
embedded. This study was approved by the internal review board
of the UKA (BKF No. 2020–18) and the ethics committee of
the University of Munich (Project number 20–426, COVID-19
registry of the UKA). Informed consent was collected from the
next of kin for all included patients.
Histology and Immunohistochemistry
Evaluation of DAD-Stages
HE-stained slides of all 249 samples were evaluated by two
experienced, board-certified pathologists (TS and BM) who were
blinded to the demographic and case-related data.
TABLE 1 | Overview over demographics, comorbidities, and systemic treatment
of all 17 patients included in the final analysis.
Demographics
Age (mean/range) 73 (57–90)
BMI > 25 13 (77%)
BMI (mean/range) 33.4 (19.6–66.2)
Sex (f/m) 4/13








History of malignant disorder 3 (18%)
Treatment
ICU treatment 13 (77%)
Invasive ventilation 8 (47%)
NI ventilation 4 (24%)
ECMO 0
Renal replacement therapy 5 (29%)
I.v. antibiotics 15 (88%)
Dexamethasone 0
Full dose anticoagulation 9 (53%)
Reconvalescent Plasma 3 (18%)
Remdesivir 1 (6%)
The presence of hyaline membranes as well as thickened
alveolar walls were the required criteria for assigning a lung
lobe to the acute stage of DAD (referred to as stage 1 in this
paper). Samples with additional fibroblast proliferation were
classified as proliferative DAD (or stage 2). Samples presenting
with collagenous fibrosis were assigned the fibrotic phase (or
stage 3). Results of these analyses, among others, have been
published recently (23).
Conventional Immunohistochemistry of the Lungs
The most properly conserved sample of each lobe was
determined and subjected to further immune cell analyses.
These 83 selected samples were stained with conventional
immunohistochemical markers for CD3 (Clone 2GV6, 1:250,
Ventana, Mannheim, Germany) and CD8 (Clone CD8/144B,
ready-to-use, Cell Marque, CA, Rocklin, USA), respectively
using a Leica BOND RX (Leica, Wetzlar, Germany) to
evaluate the general responsiveness to antibody-staining. Both
antibodies were detected by horseradish-peroxidase induced
oxidation of DAB. Slides showing a satisfactory response
were deemed suitable for the multiplexed immunofluorescence
staining. Samples from one patient exhibited significant autolysis,
reducing the number of available lung lobes from 83 to 81 and
eliminating the patient from further analysis. Independently of
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FIGURE 1 | Patient enrollment flowchart. Out of 810 planned cores, 608 were included in the final analysis. “Irregular reaction to stain” refers to cores from a single
patient, that showed a reaction to the stain that was not comparable to the rest of the cores. All samples of this patient were discarded.
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and prior to this study the DAD-stage of each lobe had been
assessed by two experienced pathologists (Figure 1).
Tissue micro-arrayed slides were further stained in
conventional immunohistochemistry with markers for CD80
(ab254579Rb pAb, 1:800, abcam, Cambridge, UK) and CD86
(ab269587 Rb mAb, 1:50, abcam, Cambridge, UK), using the
aforementioned DAB detection system. A double stain on
CD11c (clone 5D11, 1:2 ready-to-use, Cell Marque, CA, Rocklin,
USA) and CD83 (1:100, PA5-83558, ThermoFisher, Waltham,
Massachusetts, USA) was performed, with DAB for CD11c and
Fast Red for CD83.
Conventional Immunohistochemistry of Lymph Nodes
In an attempt to examine our results we stained pulmonary
lymph nodes of the autopsy cases with the aforementioned
CD11c antibody. We were able to assess 13 lymph nodes from
9 patients, 4 mediastinal, and 9 hilum lymph nodes. The lymph
nodes were divided in three groups. Group 1 drained lung lobes
of a mean DAD-stage below 1, group 2 drained lobes of a mean
stage below 2, group 3 drained lobes of a mean stage below 3. As
controls, in all 2021 autopsy cases, we looked for lymph nodes in
cases with non-neoplastic and non-inflammatory causes of death.
Three cases matched the criteria, out of which one had to be
discarded due to poor fixation.
Tissue Microarray (TMA) Construction
On the basis of whole slide scans (Pannoramic scan II, 3D
Histech, Budapest, Hungary) and by using a fully automated
system (TMAGrandMaster by 3D Histech, Budapest, Hungary),
we prepared tissue microarrayed blocks containing 10 cores of
each lung (core diameter: 1.5mm), with a maximum of 85 cores
per block.
TMA of COVID-lymph nodes (diameter 1.5mm) were
constructed manually, using a Beecher Manual Tissue Arrayer
(Model MTA-1, Estigen OÜ, Tartu, Estonia).
Staining
An HE- and a multiplexed immunofluorescence-stain were
performed on one slide each of a microarrayed paraffin
block. For immunofluorescence staining, we used a kit with
antibodies against CD20, CD68/CD168, CD11c, and MHC Class
II (UltiMapper I/O APC-Kit, Ultivue, Cambridge, MA, USA)
according to the manufacturer’s protocol.
Image Processing
After staining, all slides from the TMA-blocks were scanned
(Pannoramic Scan II scanner, 3D-Histech, Budapest, Hungary).
Scans were obtained in 20x magnification, with automated
calculation of the exposure time for each of the channels (DAPI,
FITC, TRITC, Cy5, Cy7) of the multiplexed immunofluorescence
stain. For further analyses of the virtual slides, we used the
Multiplex Phenotyping Module by Visiopharm (Visiopharm,
Hørsholm, Denmark).
We discarded all cores that had significant overlap with the
neighboring cores (which rendered interpretation impossible)
due to processing issues, got crumpled or were not stained
FIGURE 2 | MHC class II expressing mDC found in a non-DAD lung lobe.
Upper left image: Activated Channels: DAPI, Cy5 (orange, CD11c stain) and
Cy7 (MHC class II stain). The comparatively weak CD11c signal can be seen
alone in the upper right image. The lower left image shows Cy7 and proves a
massive upregulation of MHC class II in this particular dendritic cell. The lower
right image shows the interpretation by Visiopharm AI. A salmon pink mask
marks a CD11c+ MHC II+ cell. Grey: Other cells (negative or below a certain
threshold for markers but with a detectable nucleus in the DAPI channel).
appropriately. Areas with lots of cell debris and strong FITC-
noise interfering with the analysis were excluded from the
analysis (Figure 1). This reduced the core sample count to 71 and
the number of patients included to 17.
Artificial Intelligence (AI) Analysis
The Multiplex Phenotyping Module by Visiopharm
(Visiopharm, Hørsholm, Denmark), an AI-based software
was trained to identify and count the different cells by surface
antigen expression.
This approach offers the opportunity of automatically
evaluating the cell count, not on a systemic, but a local level. It
furthermore erases the need for complicated cell extraction and
resulting artifacts, a problem dendritic cells are particularly prone
to (17).
A pre-trained, deep-learning based Nuclei Detection APP
by Visiopharm (detecting DAPI-signals) was trained on a
representative selection of the slides (∼189,000 iterations)
and then used to label and count all nuclei of each lung
core (Figure 2). These labels provide the basis for further
analysis by the Multiplex phenotyping module. The Phenotyping
Module automatically categorizes the cells according to their
antigen expression.
IHC Analysis
Single-stain (CD80 and CD86) and double-stain (CD11c +
CD83) were digitalized by a 3D Histech PANNORAMIC 1000
scanner. The resulting .mrxs-files were viewed with 3D Histech’s
own Case Viewer software. The double stain slides were viewed
unaltered and counted manually. CD80 and CD86-stained slides
were viewed using the “Gradient map visualization” plugin,
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which creates a heat map based on brown color signals in a
digital slide and was developed for conventional IHC specifically
(24). Cells surrounded by at least 50% intense positive signaling
were counted as positive. For CD80, the gamma-value of all
digital slides was set to 1.8 to suppress background and weak
stain signals. Manual counts by LB were afterwards evaluated
by a board-certified pathologist (BM). BM recounted a sample
of roughly 10% of all manually counted slides. The count results
were fit in a simple linear regression model [R²= 0.9019 (double
stain); R²= 0.8228 (CD80 and CD86 count)]. CD11c stains of the
lymph nodes were estimated by LS and BM.
Statistical Analysis
The remaining 610 cores were assessed individually, whereas
data of one lung lobe was compiled afterwards and statistically
analyzed as a unit. To ensure comparability of lung lobes
with a differing number of conserved cores, the cell count of
the observed cell phenotypes in one lobe was interpreted in
relation to the total number of nuclei in the lobe (for example
“Macrophage Fraction” refers to the macrophage count relative
to the total number of counted nuclei in the same lobe).
As cell counts showed no normal distribution, a Kruskal-
Wallis test was performed on each of the mentioned cell counts
to detect significant differences of the median for stages 0–2. The
findings of stage 3 cores were not included for statistical testing
due to the low sample size of only three remaining lobes. A
Mann-Whitney-U test was used afterwards to specifically detect
which two of the groups differed significantly. A p < 0.05 was
considered significant.
We fit a simple linear regression model to correlate viral load
and mDC maturation using GraphPad Prism. Data of viral load
(Ct values of each lobe) were taken from the work by Hirschbühl




Out of 71 lung lobes from a total of 17 patients, nine were
classified as non-DAD, 16 as stage 1, 43 as stage 2 and 3 as stage
3 DAD (for an overview of the selection process see Figure 1).
Five patients showed the same stage in all analyzed lobes, two of
which were full body autopsies. Two cases presented with lobes
that showed more than two different stages.
Conventional Immunohistochemistry of the
Lung
CD3 and CD8
All but two slides showed a sufficient reaction to the CD3 and
CD8 stain, with abundant CD3 infiltrates and a rather scarce and
dispersed reaction to CD8.
CD80
The median count of CD80+ cells showed no statistically
significant differences between non-DAD and stage 1 lobes or
stage 1 and 2. The difference between non-DAD and stage 2 lobes
showed a statistical significance (p= 0.046, Figure 3).
CD86
The count of CD86+ cells varied to a greater extend, showing a
sharp decline in stage 1 compared to non-DAD and an increased
count in stage 2. Both differences were non-significant by a
narrow margin (p= 0.0557 and p= 0.0575, Figure 3).
CD11c + CD86 Double Stain
Resembling a similar pattern as the CD86 count, the count of
CD11c+CD86+ cells was lower in stage 1 compared to non-DAD,




In conventional IHC we found a rather constant CD11c+ cell
count throughout groups 2 and 3 (withmDCsmaking up roughly
1/3 of all cells). Only two lymph nodes could be assigned to
group 1. Both of these showed a higher CD11c count (around
2/3 of all cells). Both control lymph nodes showed roughly the
same distribution as groups 2 and 3. Statistical analysis was not




No statistically significant difference was detected in the CD20-
Fraction (∼p= 0.2014).While B-lymphocytes accounted only for
a very small number of the cell population, three cores showed
larger accumulations of CD20+ cells, possibly representing
germinal centers. Two of these germinal centers were found in
non-DAD lobes and one in a stage 2 sample.
CD68/163
Cells positive for CD68 or CD163 were counted as macrophages.
All stages as well as non-DAD lungs showedmassive macrophage
infiltration. Macrophages represented a large portion of all
investigated cells, with no significant differences between the
stages (p= 0.7939) (Figure 3).
A substantial portion of macrophages expressed MHC class
II proteins. The differences were not statistically significant (p =
0.1952, data not shown).
CD11c
Five outliers were detected (four in stage 2 and one in non-
DAD) and subsequently removed. Two of the outliers showed
an overall weak CD68/163 signal (and in turn an unusually low
macrophage count), which might have led to a misclassification
of macrophages as mDC.
We detected an increase in the fraction of dendritic cells
(CD11c+, or CD11c+MHC II+) from non-DAD toward later
stages. This increase was not significant when comparing non-
DAD to stage 1 (p = 0.4896) or stage 2 (p = 0.4605) lung lobes.
There was a statistically significant (p = 0.0329) raise in the
dendritic cell fraction from stage 1 to stage 2 (Figure 3). CD11c+
cells made up 0.44% of all counted cells in stage 1 and 0.88% in
stage 2. Likewise, the count of mDC in stage 3 lobes showed a
non-significant increase in comparison to stage 2 samples.
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FIGURE 3 | Cell populations in relation to the DAD-Stages (median with 95% CI). The top images show the results of multiplexed immunofluorescence, while the
bottom images show the results of conventional IHC. Top left: Fraction CD68/CD163 positive cells in relation to the total cell count. Top middle: Fraction of myeloid
dendritic cells in relation to all counted nuclei. Top right: Fraction of myeloid dendritic cells expressing MHC class II in relation to all CD11c+ cells. Bottom left: Average
of CD80+ cells per 1.5mm diameter lung core. Bottom middle: Average of CD86+ cells per 1.5mm diameter lung core. The differences were non-significant for
non-DAD vs. stage 1 (*p = 0.0557) and stage 1 vs. stage 2 (**p = 0.0575) by a narrow margin. Bottom right: Average of CD11c+CD83+ cells (double staining) per
1.5mm diameter lung core.
No significant difference was found in the ratio of
CD11c+MHC II+/all CD11c positive cells (Figure 3).
DISCUSSION
In this retrospective study, we performed an analysis of the
immune cells involved in SARS-CoV-2 induced DAD based
on 19 cases of the Augsburg autopsy series (23) using a
multiplexed immunohistochemistry approach. We found an
increased number of dendritic cells accumulating in later stages
of DAD. This is most likely attributable to a combination of an
impaired upregulation of maturation markers and a subsequent
failure of homing to lymph nodes. Ultimately, an effective T cell
response is prevented.
Methodology
The UltiMapper kits rely on antibodies marked with a DNA
sequence unique for every antibody-type. Signal amplification
is achieved by in-situ amplification, reducing the risk of
background noise compared to Tyramide Signal Amplification-
based methods (25). This allows for the simultaneous use
of up to eight different antibodies. Analyzing the generated
multidimensional dataset (considering the simultaneous use of
four different antibodies can indicate 24 = 16 different states
for a single cell) makes AI-based analysis almost mandatory.
Visiopharm software has already been used in peer-reviewed
studies for analyzing conventional immunohistochemistry and
multiplexed immunofluorescence (26, 27).
Dendritic Cell Migration and Maturation
Depending on their maturation state, dendritic cells express
a variety of surface antigens and receptors. Chemokines like
CCL3 and CCL5 are produced by a wide variety of pulmonary
cells, including epithelial cells, macrophages, neutrophils and
fibroblasts (28–32). These chemokines direct circulating DCs
expressing CCR1 and CCR5 toward the lung (17, 33), whereas
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a downregulation in CCR1 and CCR5 results in impaired
migration toward the site of inflammation (34). Numerous
studies have shown CCR1 and CCR5-expressing DCs to migrate
toward a higher CCL5-concentration (28, 35, 36), in vitro as
well as specifically in airway mucosa (37). DCs in lungs have
been shown to express both of these receptors (17). Carrying
a sentinel-like function, these local immature DCs take up
and process antigens. It is only in combination with danger-
signals like pathogen-associated molecular patterns (PAMP) that
DCs start to undergo a maturation process. At the end of this
process, the matured DC has migrated to the T-cell region of
lymphoid organs and gained the ability to activate naïve T-cells
(a process also known as “licensing”). DCs are the most potent
initiators of T-cell response (18). Maturation is accompanied
by a radical shift in surface antigen expression. As mature
DCs are first and foremost professional antigen-presenting cells,
receptors for antigen presentation like MHC class I and II are
upregulated along with co-stimulating molecules like CD40,
CD80, CD83, CD86 (38–40). Chemokine receptors CCR1 and
CCR5 are downregulated, ending the stationing of the cell–a
process. Sozzani et al. (41) described as “weighing the anchor”.
CCR7 on the other hand is upregulated and aids in recruiting
the cell toward lymphatic tissue (17, 42–44). Thus, an impaired
maturation process hampers DC homing, antigen presentation
and ultimately impedes an effective T-cell response.
Immune Evasion Strategies
Some immune evasion strategies of viral pathogens, including
coronaviridae, aim at the maturation of DCs. MHC class I and
II upregulation is impaired in MERS-CoV infected DCs (45).
SARS-CoV, while able to infect monocyte-derived DCs (46), also
hampered maturation of DCs (no significant upregulation of
MHC class I, II, CD83, CD86) (47). Simultaneously, SARS-CoV
induced the expression of CCR-1 and CCR-5 (48). For SARS-
CoV-2, data so far are also pointing toward impaired maturation
ofmDCs (21, 22). It should be noted that while Law et al. reported
a significant increase in the expression of CCR1 and CCR5, they
interpreted this finding as facilitating migration from the site of
infection toward lymph nodes. To our knowledge, this does not
concur with current findings regarding these receptors (28, 35).
Interestingly, we found mDCs in stage 1 lung lobes also had
failed to upregulate MHC class II. This is noteworthy as an
inverse correlation between DAD stage and viral load has been
described previously (23). Based on the data of this study, we
attempted to fit a simple linear regression between the viral load
and mDCmaturation. A correlation could not be detected (R2 =
0.003928, p= 0.6256).
To confirm our findings, we attempted conventional IHC
staining on other DC maturation markers, namely CD80, CD86,
and CD83. The results of the CD80 count were overall non-
conclusive, although there was a detectable difference between
non-DAD and stage 2 lobes. It is likely that the results were
skewed by the overall high count of alveolar macrophages, most
of which appeared to be CD80+. CD80 has been shown to be
expressed by macrophages (49).
As the CD83 antibody proved to be rather unspecific, we
conducted a duplex stain in combination with CD11c. The
distribution of double positive cells as well as of CD86+ cells
resembled that of MHC II+ mDCs, with no detectable increase
of activated DC in stage 1. Even more so, stage 1 lobes showed
a significantly lower count than stage 2 lobes in the double stain
[and a near significant difference to non-DAD as well as stage 2
in CD83 (Figure 3)].
Considering the fairly low number of available lymph nodes,
especially in group one (including two cases only), the results
should be interpreted very cautiously. Assuming the higher
CD11c+ count of the two cases of group 1 is representative and
does not present outliers, one could argue that this indicates
an increased DC homing in very early COVID-lungs (hence a
physiological response to a pathogen). In some cases though, viral
immune evasion might lead to an ineffective immune response
(partially caused by impaired DC homing) and to development
of DAD, represented by groups 2 and 3. It should be noted that
group 2 also drained lung lobes in stage 1. This interpretation is,
however, highly speculative.
Hypothesis
The simultaneous induction of receptors tying the DCs to
inflammatory foci and subsequent impaired maturation are
possible explanations for our findings. While immature dendritic
cells keep getting recruited, they ultimately fail to fulfil their
primary goal: homing to lymph nodes and activating T-
lymphocytes. This results in an observable accumulation of
dendritic cells in the lungs and prevents an effective T-
cell response.
One recent study by Onodi et al. reports a SARS-CoV-
2 induced significant upregulation of maturation markers in
(CD11c−) plasmacytoid predendritic cells specifically (50), a
subtype of DCs that is similar tomDCs regarding some functions,
but of lymphoid origin. Our study, by design, only reports on
CD11c+ mDCs. Considering the different changes of both pDCs
and mDCs to COVID-19 in cell count alone, it is reasonable to
assume that the molecular response could also vary to a greater
extend. Further research needs to be conducted to evaluate the
similarities or differences in the molecular reaction of both
DC types.
It is not unlikely that severe DAD might cause an increased
release of chemokines compared to earlier stages, thus causing
an intensified recruitment of DCs to foci of advanced lung
damage. It has indeed been established that the cytokine storm
in severely affected patients explicitly implies elevated levels of
CCL3 amongst other cytokines (51). Conclusive data discussing
a possible correlation between cytokine levels and DAD stage
specifically have not yet been published.
Furthermore, we did not detect an increased number of
macrophages in later stages. Monocytes are closely related to
mDCs and are known to rely on a similar pattern chemotactic
factors for trafficking toward inflammation (52). This renders
an elevated chemokine level in later stages even less likely to be
causal for the increased local mDC count.
There are no approved drugs to specifically induce DCs
maturation. Recent studies are investigating the possible use of
CCR5-inhibitors in COVID-19, primarily targeting monocyte
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trafficking (53, 54). Future works might uncover possible effects
on mDCs.
Limitations
There are some limitations to this study.
Post-mortem investigations are prone to autolysis,
possibly affecting the results. However, as insightful as in
vivo investigations might be, lung biopsies from COVID-19
patients with ARDS are not justifiable.
Although our study included only 17 cases and should thus be
interpreted with caution, these cases represent roughly 77% of all
COVID-19 deceased of the first wave at the UKA. Unfortunately,
we were not able to acquire a sufficient number of lymph nodes
for a conclusive analysis, which might have further elucidated
our hypothesis.
Lastly, CD80, CD83, and CD86 show varying specificity for
activated dendritic cells, impeding IHC analysis. More detailed
histological single-cell characterization could be made possible
by further development of multiplexed immunohistochemistry
in the foreseeable future.
CONCLUSION
So far, our evidence appears to attribute the main cause for
accumulation of DCs mainly to a disrupted maturation process
in fatal COVID-19 cases. Given the higher viral concentration
in stage 1 lung lobes, these samples would be expected to at
least hint an increased count of mDC expressing maturation
markers in comparison to later stages. On the contrary–
while the absolute count of CD86+ and CD11c+CD83+ cells
needs to be viewed in the context of the overall larger mDC
population in later stages, the CD11c+MHC II+ fractions
directly indicate a near constant share of activated mDCs.
In summary, dendritic cells failing to adequately prompt an
adaptive immune reaction might be another component in the
mismanaged immune response of severe COVID-cases. Given
that SARS-CoV-2 is likely to remain an immense public health
issue in the near future, immune evasion strategies need to be
further examined.
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